List of Marijuana/Cannabinoid-Derived Drugs Companies in United States - 50

180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world's biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company's primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).

Advion is a manufacturer and supplier of mass spectrometers and analytics systems for life science and pharmaceutical sectors.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Anresco offers a full range of microbiological services including routine QA testing, FDA Detention Without Physical Examination (DWPE) testing, shelf life studies, inoculation challenge studies, validations of food safety programs (e.g. for compliance with HACCP), and FSMA mandated environmental testing. With decades of experience working with manufacturers, importers, product developers, and more, their microbiologists have the professional expertise to help ensure the safe consumption of all perishable food products.

At Asterra Labs, we are pharmaceutical scientists and industry veterans with a passion to innovate, develop, and manufacture a pharmaceutical-grade line of safe, beneficial wellness products and alternative medicines.

Bakhu Holdings, Corp. produces, manufactures, and sells cannabis-related byproducts for medical, food additive, and recreational use. The company was founded in 2018 and is based in Long Beach, California.

Market opportunities created by evolving legislation legalizing recreational use of cannabis is generating a significant need for advances in rapid and accurate drug testing technology. Buzzkill Labs is developing next generation technology that will combine patented noninvasive sample collection methodology with scientifically validated laboratory detection and quantitation technology. Buzzkill Labs products will address the growing need for:SAFETY IN THE WORKPLACESUSPECTED IMPAIRED DRIVING BY LAW ENFORCEMENTFAST AND ACCURATE TESTING BY MEDICAL AND DRUG TREATMENT CENTERS

Medical Jane is an online resource that allows users to learn more about the medicinal benefits of cannabis, review different strains of cannabis and dispensaries, and get involved as an activist. The site's tools help patients manage their health, find quality dispensaries, and determine which cannabis strain is appropriate for their particular ailment. Medical Jane strives to be a trusted, independent platform that connects a dedicated following of medical marijuana patients, caregivers, and cannabis-activists alike. Learn more at www.medicaljane.com.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

CB Therapeutics is an innovative producer of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems. CB Therapeutics' expertise in synthetic genomics, bio-engineering and cellular production processes can produce a broad range of phytochemicals faster, more sustainably, at greater yields and with higher purity, consistency and efficiency than competitive platforms. CB Therapeutics is focused on the discovery, research, development and production of tryptamines, cannabinoids and other molecules and compounds to advance Neuroscience and bring therapeutics to market to solve mankind's most challenging mental healthcare and social problems.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Resident company JLabs San Diego focused on the development of immunotherapy for substance abuse.

CNBX Pharmaceuticals is a publicly traded company (CNBX: OTCQB) and developer of the world's first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on the company's novel and proprietary formulation CNBX™️ RCC-33.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, and Grassroots provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. Our mission is to improve people's lives by redefining how medicines are delivered and experienced.

Centrally located in the Bluegrass State of Kentucky, Demeetra has built extensive gene editing know-how, complementing our internally developed as well as globally sourced portfolio of intellectual property. Our scientific team is composed of experts with diverse backgrounds in gene editing, ranging from microbes and plants, to mammalian cells. Scientific achievements include being the first to successfully edit plants and yeast with our precise Cas-CLOVER technology. Demeetra's core focus is developing and optimizing gene editing technologies in commercially applicable systems. We transfer this new knowledge to our partners and provide simple commercial licenses with freedom to operate. We have experience in partnering and out-licensing with top pharmaceutical, biotech, and agtech companies. Our team works closely with collaborators to ensure successful implementation of Demeetra's gene editing technologies for their specific application.

We apply modern methods in agricultural biochemistry and genetics to dramatically improve cannabis varieties. These improvements ensure an unmatched experience for the cultivator and consumer alike.

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric's lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its second program, the EVM301 Series, to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.

Infusing Innovation In Everything We Do Looking for hemp-derived CBD ingredients of the highest quality, purity and consistency? Need a proven source for premium bulk and differentiated finished goods, whose mandate to champion innovation, science and compliance leads the field? Explore how the beneficial properties of CBD can enhance your product’s impact and value — in food and beverage, creams and other topicals, pet products and more. Trust a genuine industry pioneer. Partner with GenCanna. Since our inception in 2014, GenCanna has remained at the vanguard of today’s now booming CBD industry, because our influential founders helped create it. Literally. Vetted, tested and proven over time, this makes us your smartest, surest choice in a full-service CBD partner. Our roots extend back to the earliest days of cannabis legalization and reform. GenCanna helped lead the introduction of Kentucky’s groundbreaking 2014 Hemp Pilot Program. We continue spearheading regulatory initiatives that open and accelerate industry growth. In short, GenCanna has remained at the heart of it all, earning the highest industry certifications, product validations and compliance accreditations to this day. Our scalable, premium-quality derivatives and differentiated finished goods bear witness to GenCanna’s unbridled commitment to excellence: • High-Quality Cannabinoid Isolates and Distillates • Premium Bulk Broad-Spectrum and Full-Spectrum Ingredients • Water-Soluble Liquids and Soluble Powders • Reserve Oils and Bottled Custom Oil Drops • Superior Custom Formulations: -Gummies -Capsules, soft gels, tablets, and other supplement form factors -Food and beverages -Broad range of cosmetics and topicals -Health and wellbeing topicals -Pet products • Turnkey Private Label Programs • White Label Products … you name it, we’ll infuse it! Ready to achieve the next level in CBD success? RELIABLE. INNOVATIVE. GENCANNA. Premium CBD ingredients that formulate profitability for you.

GT Molecular develops ultrasensitive Molecular Assays, Digital PCR and qPCR Tests End-to-End solutions for cancer detection and waterborne pathogens including SARS-CoV-2. Detect as little as 1-3 molecules of target DNA

Kannalife Sciences, Inc. ("Kannalife"), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "‘507 Patent"). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by TIME Magazine/SI as a "super-CBD" and was recently awarded U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy et al.". Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"​). <​iframe width="560"​ height="315"​ src​="https://www.youtube.com/embed/LWLbe9m4JWo"​ frameborder="0"​ allow="autoplay; encrypted-media"​ allowfullscreen><​/iframe>

Kannalife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next-generation pharmaceutical and phyto-medical products. The company is based in Doylestown, Pennsylvania and is known for its globally patented anti-inflammatory technology. Kannalife Sciences, Inc. is dedicated to the development of breakthrough therapeutics targeted for the treatment of inflammation and neurodegenerative diseases.

Lila is a technology company pioneering the application of artificial intelligence to transform every aspect of the scientific method.

Medicinal Genomics uses state-of-the-art DNA technology to better understand cannabis genetics and develop products that help growers, dispensaries, and testing laboratories ensurethe safety and quality of cannabis.

MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the adverse side effects of cannabis plant extracts.

The global leader in continuous flow thermal sterilization. MTI Bioscience services the biotech, biopharmaceutical manufacturing, and biofuel industries for sterilization of growth media.

NeuroTherapia, Inc. is a clinical-stage company developing oral, small molecule therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation. The company was founded in 2015 by the Cleveland Clinic and two of its physician scientists.

Researchers and Developers of Cannabinoid-Based Pharmaceuticals in Accordance with U.S. Food and Drug Administration (FDA) Pre-Clinical and Clinical Pathways

A life sciences company modernizing the way medicines are taken. Our mission is to improve patient outcomes through our next generation therapeutic delivery system, the Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. With our proprietary manufacturing processes and state of the art cGMP-compliant facility in the U.S., we have developed our first product candidate, ORAVEXX™, a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and provide a safe, alternative treatment option to opioids. We are empowering the medical community by partnering with leading research institutions and physicians to support multiple FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to determine the safety and efficacy of CBD for the management of pain and inflammation.

Orochem Technologies Inc. has manufactured sample preparation products, chromatography columns, proteomics and oligo research products, and positive pressure processors in the USA since 1996. Orochem offers final products, contract synthesis of resins and oligo, and contract packing services. Orochem provides Simulated Moving Bed (SMB) Chromatography technology for the laboratory scale, pilot scale, and large-scale purification of commercially viable molecules for its customers worldwide. Orochem's products and services for Simulated Moving Bed Chromatography include the synthesis and manufacture of stationary phases "tailored for specific separations", a uniquely engineered SMB system, and the installation and commissioning of the SMB systems at customer sites with well-trained Orochem technical service engineers. Orochem owns several manufacturing facilities around the world. The Naperville, Illinois, USA site has about 84,000 square feet of manufacturing area where most of the Membrane Filter Plates, Silica manufacturing, Silica bonding, Solid Phase Extraction products, and HPLC Columns are manufactured. Orochem India, Mumbai has a 20,000-square-foot facility and manufactures Sample prep products for Discovery and clinical research organizations in Asia. Simulated Moving Bed chromatography systems are designed, built, and assembled completely at our US locations in Naperville Illinois.

PathogenDx, Inc. (PDx) is a biotechnology company that develops testing kits, automation, and software to detect pathogens in plants, food, and the body. The company's patented multiplexed molecular testing technology, Dynamic Dimensional Detection (https://pathogendx.com/science/) or D3 Array™, can rapidly detect and identify up to 50 pathogens simultaneously, in a single well test, in less than a single shift providing triplicate data per target/analyte for confidence and certainty in results with a simple and easy process. Our technology is equipment agnostic, and our analytics is automated through our cloud-based software. Our mission is to provide testing technology and solutions for the clinical, food, and agricultural testing markets for Better and Health and safety.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

Phytecs is exploring product development derived from its research conducted across the globe: North and South America, Europe and Israel. Phytecs researches compounds and derivatives from plant species to create tomorrow’s medicines. These plants produce compounds that interact with the endocannabinoid system in many different ways, from mimicking endocannabinoids to slowing or accelerating the enzymes that metabolize them.

Quantum BioPharma is at the forefront of biotechnology, committed to advancing scientific innovation and transforming lives. Our groundbreaking research is dedicated to the development of life-saving treatments for neurodegenerative diseases, with a focus on Multiple Sclerosis (MS). Through our unwavering commitment to excellence, we are pioneering the development of Lucid-MS, a potential therapeutic aimed at remyelinating neurons in the brain and spinal cord. Our vision is to restore abilities and improve the quality of life for those affected by MS. As we advance our compounds through rigorous preclinical and clinical phases, we remain steadfast in our mission to turn scientific breakthroughs into reality. Join us in our pursuit of a brighter, healthier future, where innovation meets hope, and science saves lives.

RS BioTherapeutics is a research, development, and commercialization company focused on developing life-changing medicines for pulmonary diseases. The company's mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of these medicines.

Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling inflammation-based diseases such as viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, opioid withdrawal and even the infamous hangover. Using our patented proprietary technology of “next generation anti-inflammatories” and the accelerated 505(b)2 pathway, we’re addressing the root causes of autoimmune inflammation—much like how Ozempic targets metabolic inflammation.. Our mission: to transform how we treat inflammation and reshape the business of pain relief for the betterment of humanity..

Serina Therapeutics is a privately held biotechnology company located in Huntsville, Alabama. We have developed a proprietary, clinically-validated polymer technology based on the water-soluble polymer poly(oxazoline). We call it POZ for short. Please visit our website at www.serinatherapeutics.com and review the exciting work we are doing in vaccines, Parkinson's disease, pain, oncology and cannabinoid science.

Skye Bioscience, Inc. is a pharmaceutical company focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially with a focus on modulating the system for the treatment of glaucoma and other diseases. They are developing proprietary cannabinoid derivatives for therapeutic use.

Teon is a clinical-stage company targeting metabolic signaling pathways and pioneering the development of GPCR immunotherapies in difficult-to-treat cancers.

THC Design is the leader in premium cannabis cultivation. Estate grown, single-sourced flower provides consistent experiences with quality and safety across a wide spectrum of brands. Through moral and corporate transparency, THC Design aims to inspire each person and community through the art and science of flower. By partnering with leading scientists in various fields, THC Design hopes to break new ground in the cannabis industry. We are committed to making scientific advances in identifying the roles of not only THC and CBD, but also the dozens of other therapeutic compounds in cannabis. This will help us develop better plants that can more accurately treat disease and ailments. Building a community and contributing our voice to the cannabis industry is extremely important to us. We support national and local advocacy groups to address legalization, access, and research of cannabis. We meet with lawmakers and policy writers to ensure fairness in the ongoing organization and regulation of cannabis in California.

Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products. With a world-class team of scientists collaborating in a state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science. Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp. Our solutions have broad applications across industries. Visit www.traitbio.com to learn more.

Verda is bringing basic scientific expertise to product formulation and dosing to medical cannabis products.

Vireo was founded as a pioneer in medical cannabis in 2014 and is fueled by an entrepreneurial drive. Vireo subsidiary companies cultivate and manufacture a wide variety of high-quality cannabis strains and products for sale through wholly-owned retail dispensaries and licensed third-party dispensaries, with a relentless focus on delighting customers and serving the communities in which we live and operate.

Our mission is to provide you with answers that can't otherwise be found because this information is unique to only YOU! Knowledge equals the power to work smarter and not harder; this is a key factor to achieving optimal results in any aspect of life but here at MelixGX™ it is particularly relevant to one's success in accomplishing the highest level of health, fitness, and overall well-being that many of us strive for. MelixGX™ was initially intended to focus on the fitness aspect of health and the countless number of contributing factors. These factors include the necessities (exercise regimen, diet, supplements & more) specific to every individual's body type that enable s/he to achieve their goals; our final product MelixFit™. Following this extensive research, we discovered the most common battles millions of Americans face each day, this inspired us to explore the many benefits of Cannabis. The correct strain (again, specific to one's DNA) has inimitable capabilities that include but are not limited to aiding in physical recovery, effectively and efficiently battling chronic pain, anxiety, depression, addiction, insomnia and so much more. Our final product MelixMJ™. Through sophisticated advances in technology, our knowledgeable and skilled geneticist will decode your DNA to provide you with the most analytical breakdown possible. Your DNA has all the answers, let MelixGX™ tell you what they are saying. Visit melixgx.com to learn more, and follow us on Facebook and Instagram: https://www.facebook.com/dnatestingkit/ https://www.instagram.com/melixgx/

ZeptoMetrix, an antylia scientific company, brings together some of the world's leading scientists in the fight against infectious disease. We are proud to offer an extensive range of research products and services that are continuously expanding. Our Mission "Partner to our Customer" is the basis for our successful collaboration with scientists across the globe.

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions. Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases. Acquired by Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) on Oct. 11, 2023.